Real ‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer
ConclusionChemotherapy combined with rh ‐endostatin was more effective than chemotherapy alone for non‐driver gene mutation NSCLC patients. The administration of rh‐endostatin for 7 days at 15 mg/m2 was non ‐inferior to 14 days at 7.5 mg/m2 in prolonging patients ’ PFS. Further evaluation should be conducted before its application in clinical work.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Zhongtai Wang,
Hui Zhang,
Chunhua Zhou,
Xiaoyan Long,
Rui Guan,
Nong Yang,
Yongchang Zhang Tags: ORIGINAL RESEARCH Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study